Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis | Zendy

Vishal Ranpura | Zendy; B. Pulipati | Zendy; David Chu | Zendy; Xiao Zhu | Zendy; SzuYuan Wu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis

Author(s) -

Vishal Ranpura,

B. Pulipati,

David Chu,

Xiao Zhu,

SzuYuan Wu

Publication year - 2010

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1038/ajh.2010.25

Subject(s) - medicine , bevacizumab , meta analysis , relative risk , confidence interval , incidence (geometry) , randomized controlled trial , oncology , cancer , surgery , chemotherapy , physics , optics

Hypertension is associated with the use of bevacizumab, an angiogenesis inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated with bevacizumab is unclear. We performed a systematic review and meta-analysis of published randomized-controlled clinical trials (RCTs) to assess the risk of high-grade hypertension in cancer patients treated with bevacizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research